Virchow Medical raises $4M seed to scale biopsy specimen stewardship
What's the deal? Virchow MedicalDealroom has a profile for this one. Try Dealroom →, a La Jolla-based medtech startup, has closed a $4 million seed round led by Cerberus VenturesDealroom has a profile for this one. Try Dealroom →. Chenny Zhang of Cerberus Ventures will join the company's board.
The startup makes the Crow's Nest Biopsy Catchment System, a device that captures tens of thousands of tumour cells from biopsy needles that would otherwise be thrown away. It also operates the Virchow Vault, a liquid specimen biorepository designed to store and scale those samples for molecular testing.
The funding will go toward completing the Virchow Vault and deploying pilot programmes at additional US medical institutions.
Why now? Precision oncology depends on genomic sequencing of tumour tissue — but for 30–50% of biopsy-positive cancer patients, the formalin-fixed tissue collected during standard procedures is either unavailable or insufficient for molecular diagnostics. That's a massive gap in care.
Virchow's approach sidesteps the bottleneck entirely. Rather than relying on pathology departments to supply tissue, its system lets oncologists order molecular testing from residual cells captured at the point of biopsy. Six US medical institutions are already running concordance studies comparing results from standard tissue specimens with those from Virchow's Liquid Companion Specimens.
What could go wrong? The company is early-stage, and concordance data — while promising — still needs to clear regulatory and clinical adoption hurdles. Convincing hospitals to change entrenched biopsy workflows is no small task, even when the science is compelling.
A $4 million seed round is also modest for a medtech venture with hardware, biorepository infrastructure, and multi-site pilots to fund. Virchow will likely need to raise again soon.
The signal: Cerberus Ventures, classified as an investment fund on Dealroom, is backing a company tackling a structural inefficiency in oncology diagnostics rather than developing a novel therapeutic — a bet that infrastructure-level plays in precision medicine can scale faster and face lower regulatory risk. With Virchow Medical already at the "early growth" stage despite a modest $4 million seed, the round suggests investor confidence that the biorepository model can generate recurring revenue from existing clinical workflows.
Read more: EvoNexus
